Dual-Selective and Dual-Enhanced SERS Nanoprobes Strategy for Circulating Hepatocellular Carcinoma Cells Detection
Dual-Selective and Dual-Enhanced SERS Nanoprobes Strategy for Circulating Hepatocellular Carcinoma Cells Detection
复制标题
用于循环肝细胞癌细胞检测的双选择性和双增强 SERS 纳米探针策略
DOI：
10.1002/chem.201801133
复制
发表时间：
2018-05-11
影响因子：
4.3
通讯作者：
Sun, Zhiwei
中科院分区：
文献类型：
--
作者：
Pang, Yuanfeng;Wang, Chongwen;Sun, Zhiwei
从血液样品中检测肝细胞癌（HCC）循环肿瘤细胞（CTC）可以是用于肝癌的早期检测和治疗的非常强大的非侵入性方法。然而，含有数十亿其他细胞的血液中肿瘤细胞的极其罕见使得以足够的灵敏度和特异性捕获和鉴定CTC成为真实的挑战。在这里，磁辅助表面增强拉曼散射（Sers）生物传感器检测肝癌CTC的报道是第一次。该传感器由两个基本元件组成：抗ASGPR抗体-Fe3O4@Ag磁性纳米颗粒和抗GPC 3抗体-Au @Ag@DTNB纳米棒。根据抗ASGPR和抗GPC 3抗体的双重选择性以及MNP银壳和Au@Ag NRs Sers标签的双重增强Sers信号，可以获得人外周血样本中HCC CTC的检测限为1 cellmL（-1），线性关系为1 ~ 100 cellmL（-1）。该系统在真实的血清中表现出良好的性能，这表明它可能是一个有前途的工具，肝癌的临床诊断。
The detection of hepatocellular carcinoma (HCC) circulating tumor cells (CTCs) from a blood sample can be a very powerful noninvasive approach for the early detection and therapy of liver cancer. However, the extreme rarity of tumor cells in blood containing billions of other cells makes the capture and identification of CTCs with sufficient sensitivity and specificity a real challenge. Here, a magnetically assisted surface-enhanced Raman scattering (SERS) biosensor for HCC CTC detection is reported for the first time. The biosensor consists of two basic elements: anti-ASGPR antibody-Fe3O4@Ag magnetic nanoparticles and anti-GPC3 antibody-Au@Ag@DTNB nanorods. According to the dual-selectivity of the anti-ASGPR and anti-GPC3 antibodies and the dual-enhancement SERS signal of the MNPs silver shell and the Au@Ag NRs SERS tags, a limit of detection of 1cellmL(-1) for HCC CTC in human peripheral blood samples with a linear relationship from 1 to 100cellsmL(-1) can be obtained. The system shows good performance in real serum, which suggests it may be a promising tool for HCC clinical diagnosis.